ArticleEuropean journal of heart failure2025
Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.
Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026.Obesity pillars · 2026Review
- Tectorigenin alleviates HFpEF by targeting the EGFR-EGR2-Acot1 axis to improve myocardial lipid metabolism.Acta pharmacologica Sinica · 2026Article
- Article
- Integrative Multi-Omics Profiling of Dynamic Body Mass Index-Systolic Blood Pressure Trajectories in Obesity for Precision Risk Stratification of Heart Failure Subtypes.Biomedicines · 2026Article
- Heart failure and preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance.European heart journal · 2026Review
- Adipose Tissue, Natriuretic Peptides, and HFpEF: Clinical Implications of the Obesity Paradox.Biomedicines · 2026Review
- Severe obesity in human HFpEF alters contractile protein function and organization.Science (New York, N.Y.) · 2026Article
- Cardio-Kidney-Metabolic Phenotypes and Adverse Clinical Outcomes in Patients With Atrial Fibrillation.JACC. Asia · 2026Article
- Triglyceride-glucose index and its derivatives, biventricular remodeling, and risk of incident heart failure: a large-scale prospective CMR study.Lipids in health and disease · 2026Article
- Polyphenols as Adjuvant Treatment for Heart Failure with Preserved Ejection Fraction (HFpEF): A Review.Antioxidants (Basel, Switzerland) · 2026Review
- Strengths and limitations of HFpEF probability scores in the era of precision medicine.Frontiers in medicine · 2026Review
- Lycopene's Role in Mitigating Obesity-Induced Cardiac Remodeling: Insights Into Inflammatory and MMP-2 Pathways.Molecular nutrition & food research · 2026Article
- Acute Heart Failure in Heart Failure with Preserved Ejection Fraction: A State-of-the-art Review from an International Expert Group.Cardiac failure review · 2026Review
- Fluid management among outpatients with chronic heart failure: a cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- Impact of kimura-takemoto atrophy classification on first-lineFrontiers in medicine · 2026Article
- Obesity Definitions and Hospital Stay in Older Adults with Heart Failure: A Post Hoc Analysis of a Prospective Cohort.Cardiac failure review · 2026Article
- Obesity Is Associated with a Lower Risk of Mortality and Readmission in Heart Failure Patients with Diabetes.Biomedicines · 2025Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document.European journal of heart failure · 2025Review
- Inflammation-resolution signalling in cardiac repair, remodelling, and heart failure.European heart journal open · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few years, new evidence on the mechanisms linking obesity with HF has been reported, particularly in relation to HF with preserved ejection fraction. Novel therapies inducing weight loss appear to have favourable effects on health status and cardiovascular risk. Against the backdrop of this rapidly evolving evidence landscape, HF clinicians are increasingly required to tailor their preventive, diagnostic, and therapeutic approaches to HF in the presence of obesity. This scientific statement by the Heart Failure Association of the European Society of Cardiology provides an up-to-date summary on obesity in HF, covering key areas such as epidemiology, translational aspects, diagnostic challenges, therapeutic approaches, and trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.